[go: up one dir, main page]

JO3620B1 - مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم - Google Patents

مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم

Info

Publication number
JO3620B1
JO3620B1 JOP/2016/0171A JOP20160171A JO3620B1 JO 3620 B1 JO3620 B1 JO 3620B1 JO P20160171 A JOP20160171 A JO P20160171A JO 3620 B1 JO3620 B1 JO 3620B1
Authority
JO
Jordan
Prior art keywords
blood
treatment
check point
pvrl2
nectin
Prior art date
Application number
JOP/2016/0171A
Other languages
English (en)
Inventor
STAMM Hauke
WELLBROCK Jasmin
Fiedler Walter
KLINGLER Felix
Original Assignee
Amgen Res Munich Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Res Munich Gmbh filed Critical Amgen Res Munich Gmbh
Application granted granted Critical
Publication of JO3620B1 publication Critical patent/JO3620B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

يقدم الاختراع الحالي مثبط ضد CD112 (نكتين-2، PVRL2)، CD155 (PVR)، جالكتين-9، TIM-3 و/أو TIGIT للاستخدام في طريقة علاج سرطان محمول عبر الدم، تحديدا لوكيميا نقوية حادة (AML). علاوة على ذلك، يقدم الاختراع الحالي تركيبة صيدلانية تتضمن مثبط ضد CD112 (نكتين-2، PVRL2)، CD155 (PVR)، جالكتين-9، TIM-3 و/أو TIGIT وخلية CAR T. يقدم الاختراع الحالي تركيبة صيدلانية تتضمن مثبط ضد CD112 (نكتين-2، PVRL2)، CD155 (PVR)، جالكتين-9، TIM-3 و/أو TIGIT وبنية جسم مضاد قادر على تضمين خلايا T.
JOP/2016/0171A 2015-08-05 2016-08-04 مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم JO3620B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562201461P 2015-08-05 2015-08-05

Publications (1)

Publication Number Publication Date
JO3620B1 true JO3620B1 (ar) 2020-08-27

Family

ID=56801503

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2016/0171A JO3620B1 (ar) 2015-08-05 2016-08-04 مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم

Country Status (23)

Country Link
US (2) US20170037133A1 (ar)
EP (1) EP3331915B1 (ar)
JP (1) JP7170532B2 (ar)
CN (1) CN108473572B (ar)
AU (1) AU2016301961B2 (ar)
CA (1) CA2996015A1 (ar)
DK (1) DK3331915T3 (ar)
EA (1) EA039307B1 (ar)
ES (1) ES2861436T3 (ar)
HK (1) HK1249524A1 (ar)
HU (1) HUE053763T2 (ar)
IL (1) IL256874B (ar)
JO (1) JO3620B1 (ar)
LT (1) LT3331915T (ar)
MX (1) MX2018001351A (ar)
MY (1) MY186582A (ar)
PH (1) PH12018500120A1 (ar)
SG (1) SG10202000914VA (ar)
SI (1) SI3331915T1 (ar)
TW (1) TWI719041B (ar)
UA (1) UA125375C2 (ar)
WO (1) WO2017021526A1 (ar)
ZA (1) ZA201708598B (ar)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2729463C2 (ru) 2013-12-20 2020-08-06 Фред Хатчинсон Кансэр Рисёч Сентер Меченые химерные эффекторные молекулы и их рецепторы
HUE061084T2 (hu) * 2015-02-19 2023-05-28 Compugen Ltd PVRIG elleni antitestek és alkalmazási eljárások
DK3259597T3 (da) 2015-02-19 2022-05-09 Compugen Ltd Pvrig-polypeptider og fremgangsmåder til behandling
US11827904B2 (en) 2015-04-29 2023-11-28 Fred Hutchinson Cancer Center Modified stem cells and uses thereof
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
US9861621B2 (en) * 2015-06-29 2018-01-09 Biomed Valley Discoveries, Inc. LPT-723 and immune checkpoint inhibitor combinations and methods of treatment
US11098130B1 (en) 2015-08-03 2021-08-24 Tasrif Pharmaceutical, LLC Antibodies and antibody fragments against the CD155 receptor and methods of use thereof
NZ745564A (en) 2016-03-01 2024-12-20 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Antibodies specific to human poliovirus receptor (pvr)
SG11201810023QA (en) 2016-05-27 2018-12-28 Agenus Inc Anti-tim-3 antibodies and methods of use thereof
CA3030765A1 (en) 2016-07-14 2018-01-18 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
KR102585976B1 (ko) 2016-08-17 2023-10-05 컴퓨젠 엘티디. 항-tigit 항체, 항-pvrig 항체 및 이들의 조합
WO2018058002A1 (en) 2016-09-23 2018-03-29 Fred Hutchinson Cancer Research Center Tcrs specific for minor histocompatibility (h) antigen ha-1 and uses thereof
CA3044664C (en) 2016-11-30 2022-11-22 Oncomed Pharmaceuticals, Inc. Methods for treatment of cancer comprising tigit-binding agents
JP7037577B2 (ja) 2017-03-15 2022-03-16 フレッド ハッチンソン キャンサー リサーチ センター 高親和性ｍａｇｅ－ａ１特異的ｔｃｒ及びその使用
WO2018204363A1 (en) 2017-05-01 2018-11-08 Agenus Inc. Anti-tigit antibodies and methods of use thereof
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
CA3063563A1 (en) 2017-05-24 2018-11-29 Effector Therapeutics, Inc. Compositions and methods for an improved antitumor immune response
KR20200021474A (ko) 2017-06-01 2020-02-28 컴퓨젠 엘티디. 삼중 조합 항체 치료제
WO2018229163A1 (en) * 2017-06-14 2018-12-20 King's College London Methods of activating v delta 2 negative gamma delta t cells
EP3484925B1 (en) 2017-07-27 2020-05-27 iTeos Therapeutics SA Anti-tigit antibodies
CN111051349A (zh) 2017-09-06 2020-04-21 弗雷德哈钦森癌症研究中心 Strep-tag特异性嵌合受体及其用途
CA3072908A1 (en) 2017-09-06 2019-03-14 Fred Hutchinson Cancer Research Center Strep-tag specific binding proteins and uses thereof
WO2019051135A1 (en) 2017-09-06 2019-03-14 Fred Hutchinson Cancer Research Center METHODS FOR IMPROVING ADOPTIVE CELL THERAPY
WO2019079777A1 (en) 2017-10-20 2019-04-25 Fred Hutchinson Cancer Research Center COMPOSITIONS AND METHODS FOR TIGIT AND / OR CD112R TARGETING IMMUNOTHERAPY OR COMPRISING THE OVEREXPRESSION OF CD226
WO2019102456A1 (en) 2017-11-27 2019-05-31 University Of Rijeka Faculty Of Medicine Immunotoxins for treating cancer
US20220267403A1 (en) 2017-12-01 2022-08-25 Fred Hutchinson Cancer Research Center Binding proteins specific for 5t4 and uses thereof
WO2019140278A1 (en) 2018-01-11 2019-07-18 Fred Hutchinson Cancer Research Center Immunotherapy targeting core binding factor antigens
MX2020008795A (es) * 2018-02-28 2020-10-08 Yuhan Corp Anti cuerpos anti tigit y usos de los mismos.
JP2021518104A (ja) * 2018-03-14 2021-08-02 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 操作された細胞、ｔ細胞免疫調節抗体、およびそれらの使用方法
CN112533948B (zh) 2018-05-31 2025-01-14 台湾醣联生技医药股份有限公司 与双触角Lewis B以及Lewis Y抗原结合的治疗性抗体
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors
US20210340201A1 (en) 2018-08-22 2021-11-04 Fred Hutchinson Cancer Research Center Immunotherapy targeting kras or her2 antigens
EP3841123A2 (en) 2018-08-23 2021-06-30 Seagen Inc. Anti-tigit antibodies
CN110511912B (zh) * 2018-08-30 2024-03-22 浙江煦顼技术有限公司 免疫细胞的功能调节
US20240165232A1 (en) 2018-09-24 2024-05-23 Fred Hutchinson Cancer Research Center Chimeric receptor proteins and uses thereof
CA3119188A1 (en) 2018-11-09 2020-05-14 Fred Hutchinson Cancer Research Center T cell receptors specific for mesothelin and their use in immunotherapy
ES2961791T3 (es) 2018-12-19 2024-03-13 Humabs Biomed Sa Anticuerpos que neutralizan el virus de la hepatitis B y usos de los mismos
US20220112283A1 (en) 2019-01-13 2022-04-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human nectin-2
CN114026116A (zh) 2019-02-20 2022-02-08 弗雷德哈钦森癌症研究中心 Ras新抗原特异性结合蛋白及其用途
EA202192252A1 (ru) 2019-03-11 2021-12-21 Фред Хатчинсон Кэнсер Рисерч Сентер Высокоавидные т-клеточные рецепторы к wt1 и их применения
WO2021007503A1 (en) * 2019-07-11 2021-01-14 Dana-Farber Cancer Institute, Inc. Targeting galectin-9 as a therapeutic strategy for t-cell exhaustion in t-cell acute lymphoblastic leukemia
KR20220050176A (ko) 2019-08-20 2022-04-22 프레드 헛친슨 켄서 리서치 센터 Wt-1에 특이적인 t-세포 면역요법
CN114630680B (zh) 2019-08-29 2024-10-11 维尔生物科技有限公司 用于治疗乙型肝炎病毒感染的抗体组合物和方法
EP3789485A1 (en) * 2019-09-06 2021-03-10 ONK Therapeutics Limited Cellular therapies for cancer
US20230057899A1 (en) 2019-12-05 2023-02-23 Compugen Ltd. Anti-pvrig and anti-tigit antibodies for enhanced nk-cell based tumor killing
EP4168118A1 (en) 2020-06-18 2023-04-26 Genentech, Inc. Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
WO2021262840A1 (en) 2020-06-24 2021-12-30 Vir Biotechnology, Inc. Engineered hepatitis b virus neutralizing antibodies and uses thereof
TW202216778A (zh) 2020-07-15 2022-05-01 美商安進公司 Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷
CN114163532A (zh) * 2020-09-10 2022-03-11 南京北恒生物科技有限公司 包含新型共刺激结构域的嵌合抗原受体及其用途
WO2022066965A2 (en) 2020-09-24 2022-03-31 Fred Hutchinson Cancer Research Center Immunotherapy targeting sox2 antigens
WO2022066973A1 (en) 2020-09-24 2022-03-31 Fred Hutchinson Cancer Research Center Immunotherapy targeting pbk or oip5 antigens
WO2022076353A1 (en) 2020-10-06 2022-04-14 Fred Hutchinson Cancer Research Center Compositions and methods for treating mage-a1-expressing disease
CN112480264B (zh) * 2020-11-27 2022-04-29 山东兴瑞生物科技有限公司 一种以tigit和pd-1为靶点的嵌合抗原受体、car-t细胞及其制备方法
CA3201767A1 (en) 2020-12-14 2022-06-23 Thomas M. Schmitt Compositions and methods for cellular immunotherapy
WO2022145879A1 (ko) * 2020-12-28 2022-07-07 연세대학교 산학협력단 면역 관문 저해제의 스크리닝 방법
TW202245838A (zh) 2021-01-26 2022-12-01 美商維爾生物科技股份有限公司 用於治療b型肝炎病毒感染的組成物及方法
EP4326773A1 (en) 2021-04-23 2024-02-28 Suzhou Neologics Bioscience Co., Ltd. Tim-3-targetting antibodies and uses thereof
AR125753A1 (es) 2021-05-04 2023-08-09 Agenus Inc Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos
TW202317602A (zh) 2021-07-15 2023-05-01 福瑞德哈金森腫瘤中心 嵌合多肽
WO2023010094A2 (en) 2021-07-28 2023-02-02 Genentech, Inc. Methods and compositions for treating cancer
TW202321308A (zh) 2021-09-30 2023-06-01 美商建南德克公司 使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法
WO2023161943A1 (en) 2022-02-28 2023-08-31 Nectin Therapeutics Ltd. Humanized antibodies against nectin-2 and drug conjugates thereof
EP4493195A1 (en) 2022-03-15 2025-01-22 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2023230439A1 (en) 2022-05-23 2023-11-30 Vir Biotechnology, Inc. Fc-engineered hepatitis b virus neutralizing antibodies and uses thereof
IL317449A (en) 2022-06-07 2025-02-01 Genentech Inc Method for determining the efficacy of a lung cancer treatment comprising an anti-PD-L1 antagonist and an anti-TIGIT antibody-antagonist
US20240425607A1 (en) 2023-06-26 2024-12-26 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
AU761587B2 (en) 1998-04-21 2003-06-05 Amgen Research (Munich) Gmbh CD19xCD3 specific polypeptides and uses thereof
DK1100830T3 (da) 1998-07-28 2004-01-19 Micromet Ag Heterominiantistoffer
EP1481993A1 (en) * 2003-05-28 2004-12-01 Xerion Pharmaceuticals AG Modulation of the poliovirus receptor function
US8076459B2 (en) 2003-10-16 2011-12-13 Micromet Ag Multispecfic deimmunized CD3-binders
WO2005107799A1 (ja) * 2004-05-06 2005-11-17 Eisai R & D Management Co., Ltd. 抗Necl-5抗体を有効成分として含む癌治療剤
WO2007042261A2 (en) 2005-10-11 2007-04-19 Micromet Ag Compositions comprising cross-species-specific antibodies and uses thereof
PE20081456A1 (es) * 2006-10-06 2008-11-27 Takeda Pharmaceutical Anticuerpo monoclonal contra nectina 2
FI2155783T4 (fi) 2007-04-03 2022-12-15 Lajien välisesti spesifinen cd3-epsilon-sitoutumisdomeeni
EP2252319A2 (en) * 2008-01-29 2010-11-24 The Brigham and Women's Hospital, Inc. Methods for modulating a population of myeloid-derived suppressor cells and uses thereof
EP3208612B1 (en) 2008-04-09 2019-09-18 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
AU2009299794B2 (en) 2008-10-01 2015-08-13 Amgen Research (Munich) Gmbh Cross-species-specific single domain bispecific single chain antibody
JP2013532153A (ja) * 2010-06-18 2013-08-15 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体
WO2012177788A1 (en) * 2011-06-20 2012-12-27 La Jolla Institute For Allergy And Immunology Modulators of 4-1bb and immune responses
WO2013026837A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
PL2748201T3 (pl) 2011-08-23 2018-04-30 Roche Glycart Ag Aktywujące komórki t dwuswoiste cząsteczki wiążące antygen
NZ709059A (en) * 2012-12-04 2016-11-25 Oncomed Pharm Inc Immunotherapy with binding agents
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
MX357011B (es) 2013-03-15 2018-06-22 Amgen Inc Anticuerpos biespecificos heterodimericos.
CA2916681A1 (en) * 2013-07-16 2015-01-22 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
TWI688401B (zh) 2013-09-13 2020-03-21 美商安進公司 用於治療骨髓性白血病的表觀遺傳因子與靶向ｃｄ３３及ｃｄ３之雙特異性化合物的組合
EP3733710A1 (en) 2013-09-25 2020-11-04 Amgen, Inc Hetrodimeric v-c-fc-v-c antibody
US10570204B2 (en) * 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
JOP20200096A1 (ar) * 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
PH12018500120A1 (en) 2018-07-23
CA2996015A1 (en) 2017-02-09
EA039307B1 (ru) 2022-01-12
EP3331915B1 (en) 2021-02-17
SI3331915T1 (sl) 2021-08-31
EA201890428A1 (ru) 2018-07-31
EP3331915A1 (en) 2018-06-13
JP2018531215A (ja) 2018-10-25
AU2016301961B2 (en) 2021-10-07
US20190077869A1 (en) 2019-03-14
UA125375C2 (uk) 2022-03-02
TWI719041B (zh) 2021-02-21
ES2861436T3 (es) 2021-10-06
LT3331915T (lt) 2021-06-10
TW201718002A (zh) 2017-06-01
ZA201708598B (en) 2021-04-28
US20170037133A1 (en) 2017-02-09
HUE053763T2 (hu) 2021-12-28
DK3331915T3 (da) 2021-05-03
IL256874A (en) 2018-03-29
MY186582A (en) 2021-07-28
CN108473572A (zh) 2018-08-31
WO2017021526A1 (en) 2017-02-09
AU2016301961A1 (en) 2018-01-18
MX2018001351A (es) 2018-05-22
CN108473572B (zh) 2021-10-15
IL256874B (en) 2022-05-01
SG10202000914VA (en) 2020-03-30
JP7170532B2 (ja) 2022-11-14
HK1249524A1 (zh) 2018-11-02

Similar Documents

Publication Publication Date Title
JO3620B1 (ar) مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
CY1124730T1 (el) Αντισωματα εναντι pd-1 και χρησεις αυτων
CY1126115T1 (el) Συνδυασμος anti-lag-3 αντισωματων και anti-pd-1 αντισωματων για θεραπεια ογκων
PH12019501253A1 (en) Anti-tim-3 antibodies for combination with anti-pd-1 antibodies
PH12019500369A1 (en) Anti-tim-3 antibodies
CY1123938T1 (el) Συνδυασμος αντισωματος αντι-cd20 και εκλεκτικου αναστολεα κινασης p13
MX2019012038A (es) Composiciones que comprenden una combinacion de un anticuerpo anti gen 3 de activacion del linfocito (lag-3), un inhibidor de la trayectoria del receptor de muerte programada 1 (pd-1), y un agente inmunoterapeutico.
CY1119799T1 (el) Συνδυασμος αντισωματων anti-kir και αντισωματων anti-pd-1 για αγωγη καρκινου
EA202091540A1 (ru) Антитела к lilrb2
MX2021000745A (es) Composiciones anti-cd112r y metodos.
MX2017013613A (es) Neoepitodos de cancer.
PH12018500815A1 (en) Antibody conjugates comprising toll-like receptor agonist
WO2016062722A8 (en) Combination
MX2017012113A (es) Combinacion de inhibidor de histona desacetilasa y anticuerpo anti-muerte celular programada-1 para el tratamiento de cancer.
MX2018000267A (es) Combinacion de inhibidores de histona desacetilasa y anticuerpo de ligando 1 de anti-muerte celular programada para el tratamiento de cancer.
PH12016501976A1 (en) Antibodies, pharmaceutical compositions and uses thereof
EA202090061A1 (ru) Применение антитела против cd70, argx-110, для лечения острого миелоидного лейкоза
DOP2020000020A (es) Anticuerpos anti-cd137
BR112018006140A2 (pt) anticorpo ou uma porção de ligação a antígeno do mesmo, composição farmacêutica, e, método para inibição de proliferação de células cancerígenas.
CR20170529A (es) Terapia combinada de un anticuerpo anti-cd-20 con un inhibidor de bcl-2 y un inhibidor de mdm2.
MX2018008008A (es) Combinacion del inhibidor hdac y anticuerpo-pd-l1 para el tratamiento de cancer ovarico.
EA201891527A1 (ru) Композиции и способы обнаружения и лечения рака пищевода
EA201891528A1 (ru) Композиции и способы обнаружения и лечения рака желудка
EA202090627A1 (ru) Способы оценки конъюгатов антитела и лекарственного препарата
MX2021001604A (es) Tratamiento del cáncer con un anticuerpo.